PF 07264660
Alternative Names: PF-07264660Latest Information Update: 19 Jun 2024
At a glance
- Originator Pfizer
- Class Monoclonal antibodies; Skin disorder therapies
- Mechanism of Action Interleukin 13 inhibitors; Interleukin 4 inhibitors; Interleukin-33 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Atopic dermatitis
Most Recent Events
- 06 May 2024 Pfizer completes a phase I trial in Atopic dermatitis (In volunteers) in USA (SC) (IV) (NCT05496738)
- 22 Aug 2023 Pfizer plans a phase II trial for Atopic dermatitis in the US (SC, Injection) (NCT05995964)
- 22 Aug 2023 Phase-II clinical trials in Atopic dermatitis in USA (SC)